Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 288
---
 6. | In 2019, a controversy has arisen between the Company and CSL Behring                                                                         
 GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020 are to be paid by the Company pursuant  
 to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the Company and CSL, whereby CSL agreed    
 to supply the Company with fibrinogen. On January 14, 2020, the Company received a termination letter, or CSL Termination Letter. In the      
 CSL Termination Letter, CSL demanded a total amount of $820, claiming it was owed the minimum purchase commitment amounts under the Framework 
 Supply Agreement not paid by the Company in 2018 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages     
 for lost profit, with an aggregate demand amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s             
 demands are baseless under the Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is         
 conditional upon first obtaining approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical    
 milestones, none of which has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor 
 to seek for its enforcement in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase          
 commitments lacks any ground under the terms of the Framework Supply Agreement and moreover, that the Company was never served with German    
 judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the applicable         
 German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are in the opinion         
 that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable German judgement      
 could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s purported ruling.               |

<div align='center'>F-38</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

The Company’s product has yet to
be approved by FDA and is still in